REFRACTORY MALIGNANT GLIOMA
Clinical trials for REFRACTORY MALIGNANT GLIOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MALIGNANT GLIOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MALIGNANT GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with tough cancers: targeted pill shows promise
Disease control OngoingThis study tests a drug called ivosidenib (AG-120) in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have come back or not responded to standard treatment. The drug works by blocking a faulty signal that helps cancer grow. The main goal i…
Matched conditions: REFRACTORY MALIGNANT GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:26 UTC
-
Targeted drug shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…
Matched conditions: REFRACTORY MALIGNANT GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Engineered immune cells take on recurrent brain tumors in early trial
Disease control OngoingThis early-stage study tests a new treatment for people with malignant glioma that has returned or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), add a special gene to help them recognize and attack the tumor, and infuse them back. The mai…
Matched conditions: REFRACTORY MALIGNANT GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…
Matched conditions: REFRACTORY MALIGNANT GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had come back or were not responding to treatment. The drug targets cancers with specific changes in FGFR genes. The main goal was to see if the drug could shrink tumors. About 2…
Matched conditions: REFRACTORY MALIGNANT GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Matched conditions: REFRACTORY MALIGNANT GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Targeted drug tipifarnib tested in kids with rare HRAS-Driven cancers
Disease control OngoingThis study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…
Matched conditions: REFRACTORY MALIGNANT GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC